Page last updated: 2024-11-03

risperidone and Neoplasms

risperidone has been researched along with Neoplasms in 7 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Treatment of delirium often includes haloperidol."9.34Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020)
"Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission."9.16Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012)
"The clinical benefit of perospirone for treatment of delirium in patients with advanced cancer is not sufficiently clear."8.12Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings. ( Inoue, S; Maeda, I; Ogawa, A; Terada, S; Yamada, N; Yoshiuchi, K, 2022)
"Oral risperidone was given once a day (0."5.43Association of the Clinical Subtype and Etiology for Delirium with the Outcome after Risperidone Monotherapy in Patients Having Cancer. ( Inoue, K; Matsuda, Y; Nakao, Y; Takemura, M; Tsuruta, R; Yabe, M, 2016)
"Treatment of delirium often includes haloperidol."5.34Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020)
"Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission."5.16Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012)
"The clinical benefit of perospirone for treatment of delirium in patients with advanced cancer is not sufficiently clear."4.12Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings. ( Inoue, S; Maeda, I; Ogawa, A; Terada, S; Yamada, N; Yoshiuchi, K, 2022)
"To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS)."3.83Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study. ( Goya, S; Kai, T; Kanemura, S; Kashiwagi, Y; Maeda, I; Matsuda, Y; Nakajima, S; Okamoto, Y; Taira, T; Takei, K; Tanimukai, H; Tokoro, A; Tokuyama, M; Tsujimoto, H; Tsujio, I; Watanabe, M, 2016)
"Oral risperidone was given once a day (0."1.43Association of the Clinical Subtype and Etiology for Delirium with the Outcome after Risperidone Monotherapy in Patients Having Cancer. ( Inoue, K; Matsuda, Y; Nakao, Y; Takemura, M; Tsuruta, R; Yabe, M, 2016)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Diamandis, P1
Wildenhain, J1
Clarke, ID1
Sacher, AG1
Graham, J1
Bellows, DS1
Ling, EK1
Ward, RJ1
Jamieson, LG1
Tyers, M1
Dirks, PB1
Inoue, S1
Maeda, I2
Ogawa, A1
Yoshiuchi, K1
Terada, S1
Yamada, N1
van der Vorst, MJDL1
Neefjes, ECW1
Boddaert, MSA1
Verdegaal, BATT1
Beeker, A1
Teunissen, SCC1
Beekman, ATF1
Wilschut, JA1
Berkhof, J1
Zuurmond, WWA1
Verheul, HMW1
Matsuda, Y2
Nakao, Y1
Yabe, M1
Tsuruta, R1
Takemura, M1
Inoue, K1
Tanimukai, H1
Tsujimoto, H1
Tokoro, A1
Kanemura, S1
Watanabe, M1
Tsujio, I1
Takei, K1
Nakajima, S1
Taira, T1
Tokuyama, M1
Kai, T1
Okamoto, Y1
Goya, S1
Kashiwagi, Y1
Kishi, Y1
Kato, M1
Okuyama, T1
Thurber, S1
Ito, H1
Harada, D1
Hayashida, K1
Ishino, H1
Nakayama, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer[NCT01539733]101 participants (Actual)Interventional2010-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for risperidone and Neoplasms

ArticleYear
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
    The oncologist, 2020, Volume: 25, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Neoplasms; Olanzapine;

2020
Treatment of delirium with risperidone in cancer patients.
    Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:5

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Hallucinations; Humans; Male; Middl

2012

Other Studies

5 other studies available for risperidone and Neoplasms

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic

2007
Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings.
    Acta medica Okayama, 2022, Volume: 76, Issue:2

    Topics: Aged; Antipsychotic Agents; Delirium; Humans; Isoindoles; Neoplasms; Psycho-Oncology; Risperidone; T

2022
Association of the Clinical Subtype and Etiology for Delirium with the Outcome after Risperidone Monotherapy in Patients Having Cancer.
    Osaka city medical journal, 2016, Volume: 62, Issue:2

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Checklist; Delirium; Female; Humans; Male; Middle Age

2016
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
    The American journal of hospice & palliative care, 2016, Volume: 33, Issue:5

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Delirium; F

2016
[Psychiatry and sleep disorders--delirium].
    Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2006, Volume: 108, Issue:11

    Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; I

2006